KYAN Therapeutics' technology platform identifies novel and effective nucleic acid therapies for MYC-driven liver cancer
Study published in Bioengineering & Translational Medicine SINGAPORE, SINGAPORE, September 17, 2022 /EINPresswire.com/ -- MYC is a transcription factor that is dysregulated in over 70% of human cancers, making it an important target that …